(Q43004346)

12 November 2017

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma (English)

1 reference

12 November 2017

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Shannon M Steinberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Peisheng Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Brian T Malik

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Andrea Boni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Tamer B Shabaneh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Katelyn T Byrne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Constance E Brinckerhoff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Marc S Ernstoff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Marcus W Bosenberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Mary Jo Turk

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

2 September 2014

1 reference

Cancer Immunology Research

12 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1044-1050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

31 May 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF-targeted therapy and immune responses to melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Vemurafenib: the first drug approved for BRAF-mutant cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230697

10.1158/2326-6066.CIR-14-0074

16 August 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25183499%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

PubMed publication ID

25183499

1 reference